Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook ...

Overview: Real-time voice interaction is becoming a defining feature of next-generation AI applications. From conversational ...

Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

Vertex is a $90bn market cap Pharma giant with a monopolistic control of the cystic fibrosis industry. CRISPR Therapeutics is an obscure - to some - Swiss Pharma focused on gene therapy, leveraging ...

Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder ...

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Vertex AI Studio is a Google Cloud console tool for building and testing generative AI models. It allows you to design and test prompts and customize foundation models to meet your application’s needs ...